Jufeng Early Participation: Shanghai resumption of business and market + lower mortgage interest rate lower limit, A shares will fluctuate upward Post date May 16, 2022 — 03:29 Post Lock Read More Yuheng Pharmaceutical: A fire accident occurred in a three-dimensional warehouse of a subsidiary – yqqlm Post date May 13, 2022 — 18:39 Post Lock Read More A fire accident occurred in a three-dimensional warehouse of a subsidiary of Yuheng Pharmaceutical Co., Ltd. Post date May 13, 2022 — 18:38 Post Lock Read More [V View 2021 Annual Report] In 2021, 60% of pharmaceutical stocks’ revenue and net profit will double, and BeiGene will become the “loss king” – yqqlm Post date May 1, 2022 — 04:00 Post Lock Read More [V View 2021 Annual Report] In 2021, 60% of pharmaceutical stocks will increase in revenue and net profit, and BeiGene will become the "loss king"-Stock Channel-Hexun.com Post date May 1, 2022 — 04:00 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG Post date April 19, 2022 — 09:35 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG Xinhua Post date April 19, 2022 — 09:30 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG PD-1 Junshi Biotechnology Listed Company_Sina Technology_Sina Post date April 19, 2022 — 07:36 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 07:31 Post Lock Read More SINBON PHARMACEUTICAL (002390): Announcement on Expected Daily Connected Transactions in 2022- CFi.CN Zhongcai Network Post date April 15, 2022 — 04:20 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of progress, and there is no substantial progress yet. Post date April 12, 2022 — 10:57 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of advancing, and there is no substantial progress yet. Post date April 12, 2022 — 10:56 Post Lock Read More Domestic PD-1 "involution" intensifies, BeiGene seeks to "break through" Europe Post date April 7, 2022 — 19:15 Post Lock Read More Shareholders of Yuheng Pharmaceuticals reduced their holdings of 37.1028 million shares to cash out about 80.142 million in the third quarter of 2021, the company lost 4.0742 million Post date April 6, 2022 — 23:30 Post Lock Read More
Yuheng Pharmaceutical: A fire accident occurred in a three-dimensional warehouse of a subsidiary – yqqlm Post date May 13, 2022 — 18:39 Post Lock Read More A fire accident occurred in a three-dimensional warehouse of a subsidiary of Yuheng Pharmaceutical Co., Ltd. Post date May 13, 2022 — 18:38 Post Lock Read More [V View 2021 Annual Report] In 2021, 60% of pharmaceutical stocks’ revenue and net profit will double, and BeiGene will become the “loss king” – yqqlm Post date May 1, 2022 — 04:00 Post Lock Read More [V View 2021 Annual Report] In 2021, 60% of pharmaceutical stocks will increase in revenue and net profit, and BeiGene will become the "loss king"-Stock Channel-Hexun.com Post date May 1, 2022 — 04:00 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG Post date April 19, 2022 — 09:35 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG Xinhua Post date April 19, 2022 — 09:30 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG PD-1 Junshi Biotechnology Listed Company_Sina Technology_Sina Post date April 19, 2022 — 07:36 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 07:31 Post Lock Read More SINBON PHARMACEUTICAL (002390): Announcement on Expected Daily Connected Transactions in 2022- CFi.CN Zhongcai Network Post date April 15, 2022 — 04:20 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of progress, and there is no substantial progress yet. Post date April 12, 2022 — 10:57 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of advancing, and there is no substantial progress yet. Post date April 12, 2022 — 10:56 Post Lock Read More Domestic PD-1 "involution" intensifies, BeiGene seeks to "break through" Europe Post date April 7, 2022 — 19:15 Post Lock Read More Shareholders of Yuheng Pharmaceuticals reduced their holdings of 37.1028 million shares to cash out about 80.142 million in the third quarter of 2021, the company lost 4.0742 million Post date April 6, 2022 — 23:30 Post Lock Read More
A fire accident occurred in a three-dimensional warehouse of a subsidiary of Yuheng Pharmaceutical Co., Ltd. Post date May 13, 2022 — 18:38 Post Lock Read More [V View 2021 Annual Report] In 2021, 60% of pharmaceutical stocks’ revenue and net profit will double, and BeiGene will become the “loss king” – yqqlm Post date May 1, 2022 — 04:00 Post Lock Read More [V View 2021 Annual Report] In 2021, 60% of pharmaceutical stocks will increase in revenue and net profit, and BeiGene will become the "loss king"-Stock Channel-Hexun.com Post date May 1, 2022 — 04:00 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG Post date April 19, 2022 — 09:35 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG Xinhua Post date April 19, 2022 — 09:30 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG PD-1 Junshi Biotechnology Listed Company_Sina Technology_Sina Post date April 19, 2022 — 07:36 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 07:31 Post Lock Read More SINBON PHARMACEUTICAL (002390): Announcement on Expected Daily Connected Transactions in 2022- CFi.CN Zhongcai Network Post date April 15, 2022 — 04:20 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of progress, and there is no substantial progress yet. Post date April 12, 2022 — 10:57 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of advancing, and there is no substantial progress yet. Post date April 12, 2022 — 10:56 Post Lock Read More Domestic PD-1 "involution" intensifies, BeiGene seeks to "break through" Europe Post date April 7, 2022 — 19:15 Post Lock Read More Shareholders of Yuheng Pharmaceuticals reduced their holdings of 37.1028 million shares to cash out about 80.142 million in the third quarter of 2021, the company lost 4.0742 million Post date April 6, 2022 — 23:30 Post Lock Read More
[V View 2021 Annual Report] In 2021, 60% of pharmaceutical stocks’ revenue and net profit will double, and BeiGene will become the “loss king” – yqqlm Post date May 1, 2022 — 04:00 Post Lock Read More [V View 2021 Annual Report] In 2021, 60% of pharmaceutical stocks will increase in revenue and net profit, and BeiGene will become the "loss king"-Stock Channel-Hexun.com Post date May 1, 2022 — 04:00 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG Post date April 19, 2022 — 09:35 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG Xinhua Post date April 19, 2022 — 09:30 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG PD-1 Junshi Biotechnology Listed Company_Sina Technology_Sina Post date April 19, 2022 — 07:36 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 07:31 Post Lock Read More SINBON PHARMACEUTICAL (002390): Announcement on Expected Daily Connected Transactions in 2022- CFi.CN Zhongcai Network Post date April 15, 2022 — 04:20 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of progress, and there is no substantial progress yet. Post date April 12, 2022 — 10:57 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of advancing, and there is no substantial progress yet. Post date April 12, 2022 — 10:56 Post Lock Read More Domestic PD-1 "involution" intensifies, BeiGene seeks to "break through" Europe Post date April 7, 2022 — 19:15 Post Lock Read More Shareholders of Yuheng Pharmaceuticals reduced their holdings of 37.1028 million shares to cash out about 80.142 million in the third quarter of 2021, the company lost 4.0742 million Post date April 6, 2022 — 23:30 Post Lock Read More
[V View 2021 Annual Report] In 2021, 60% of pharmaceutical stocks will increase in revenue and net profit, and BeiGene will become the "loss king"-Stock Channel-Hexun.com Post date May 1, 2022 — 04:00 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG Post date April 19, 2022 — 09:35 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG Xinhua Post date April 19, 2022 — 09:30 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG PD-1 Junshi Biotechnology Listed Company_Sina Technology_Sina Post date April 19, 2022 — 07:36 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 07:31 Post Lock Read More SINBON PHARMACEUTICAL (002390): Announcement on Expected Daily Connected Transactions in 2022- CFi.CN Zhongcai Network Post date April 15, 2022 — 04:20 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of progress, and there is no substantial progress yet. Post date April 12, 2022 — 10:57 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of advancing, and there is no substantial progress yet. Post date April 12, 2022 — 10:56 Post Lock Read More Domestic PD-1 "involution" intensifies, BeiGene seeks to "break through" Europe Post date April 7, 2022 — 19:15 Post Lock Read More Shareholders of Yuheng Pharmaceuticals reduced their holdings of 37.1028 million shares to cash out about 80.142 million in the third quarter of 2021, the company lost 4.0742 million Post date April 6, 2022 — 23:30 Post Lock Read More
The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG Post date April 19, 2022 — 09:35 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG Xinhua Post date April 19, 2022 — 09:30 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG PD-1 Junshi Biotechnology Listed Company_Sina Technology_Sina Post date April 19, 2022 — 07:36 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 07:31 Post Lock Read More SINBON PHARMACEUTICAL (002390): Announcement on Expected Daily Connected Transactions in 2022- CFi.CN Zhongcai Network Post date April 15, 2022 — 04:20 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of progress, and there is no substantial progress yet. Post date April 12, 2022 — 10:57 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of advancing, and there is no substantial progress yet. Post date April 12, 2022 — 10:56 Post Lock Read More Domestic PD-1 "involution" intensifies, BeiGene seeks to "break through" Europe Post date April 7, 2022 — 19:15 Post Lock Read More Shareholders of Yuheng Pharmaceuticals reduced their holdings of 37.1028 million shares to cash out about 80.142 million in the third quarter of 2021, the company lost 4.0742 million Post date April 6, 2022 — 23:30 Post Lock Read More
The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG Xinhua Post date April 19, 2022 — 09:30 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG PD-1 Junshi Biotechnology Listed Company_Sina Technology_Sina Post date April 19, 2022 — 07:36 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 07:31 Post Lock Read More SINBON PHARMACEUTICAL (002390): Announcement on Expected Daily Connected Transactions in 2022- CFi.CN Zhongcai Network Post date April 15, 2022 — 04:20 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of progress, and there is no substantial progress yet. Post date April 12, 2022 — 10:57 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of advancing, and there is no substantial progress yet. Post date April 12, 2022 — 10:56 Post Lock Read More Domestic PD-1 "involution" intensifies, BeiGene seeks to "break through" Europe Post date April 7, 2022 — 19:15 Post Lock Read More Shareholders of Yuheng Pharmaceuticals reduced their holdings of 37.1028 million shares to cash out about 80.142 million in the third quarter of 2021, the company lost 4.0742 million Post date April 6, 2022 — 23:30 Post Lock Read More
The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG PD-1 Junshi Biotechnology Listed Company_Sina Technology_Sina Post date April 19, 2022 — 07:36 Post Lock Read More The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 07:31 Post Lock Read More SINBON PHARMACEUTICAL (002390): Announcement on Expected Daily Connected Transactions in 2022- CFi.CN Zhongcai Network Post date April 15, 2022 — 04:20 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of progress, and there is no substantial progress yet. Post date April 12, 2022 — 10:57 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of advancing, and there is no substantial progress yet. Post date April 12, 2022 — 10:56 Post Lock Read More Domestic PD-1 "involution" intensifies, BeiGene seeks to "break through" Europe Post date April 7, 2022 — 19:15 Post Lock Read More Shareholders of Yuheng Pharmaceuticals reduced their holdings of 37.1028 million shares to cash out about 80.142 million in the third quarter of 2021, the company lost 4.0742 million Post date April 6, 2022 — 23:30 Post Lock Read More
The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 07:31 Post Lock Read More SINBON PHARMACEUTICAL (002390): Announcement on Expected Daily Connected Transactions in 2022- CFi.CN Zhongcai Network Post date April 15, 2022 — 04:20 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of progress, and there is no substantial progress yet. Post date April 12, 2022 — 10:57 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of advancing, and there is no substantial progress yet. Post date April 12, 2022 — 10:56 Post Lock Read More Domestic PD-1 "involution" intensifies, BeiGene seeks to "break through" Europe Post date April 7, 2022 — 19:15 Post Lock Read More Shareholders of Yuheng Pharmaceuticals reduced their holdings of 37.1028 million shares to cash out about 80.142 million in the third quarter of 2021, the company lost 4.0742 million Post date April 6, 2022 — 23:30 Post Lock Read More
SINBON PHARMACEUTICAL (002390): Announcement on Expected Daily Connected Transactions in 2022- CFi.CN Zhongcai Network Post date April 15, 2022 — 04:20 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of progress, and there is no substantial progress yet. Post date April 12, 2022 — 10:57 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of advancing, and there is no substantial progress yet. Post date April 12, 2022 — 10:56 Post Lock Read More Domestic PD-1 "involution" intensifies, BeiGene seeks to "break through" Europe Post date April 7, 2022 — 19:15 Post Lock Read More Shareholders of Yuheng Pharmaceuticals reduced their holdings of 37.1028 million shares to cash out about 80.142 million in the third quarter of 2021, the company lost 4.0742 million Post date April 6, 2022 — 23:30 Post Lock Read More
Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of progress, and there is no substantial progress yet. Post date April 12, 2022 — 10:57 Post Lock Read More Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of advancing, and there is no substantial progress yet. Post date April 12, 2022 — 10:56 Post Lock Read More Domestic PD-1 "involution" intensifies, BeiGene seeks to "break through" Europe Post date April 7, 2022 — 19:15 Post Lock Read More Shareholders of Yuheng Pharmaceuticals reduced their holdings of 37.1028 million shares to cash out about 80.142 million in the third quarter of 2021, the company lost 4.0742 million Post date April 6, 2022 — 23:30 Post Lock Read More
Yuheng Pharmaceutical: The bankruptcy and reorganization of the company's controlling shareholder is still in the process of advancing, and there is no substantial progress yet. Post date April 12, 2022 — 10:56 Post Lock Read More Domestic PD-1 "involution" intensifies, BeiGene seeks to "break through" Europe Post date April 7, 2022 — 19:15 Post Lock Read More Shareholders of Yuheng Pharmaceuticals reduced their holdings of 37.1028 million shares to cash out about 80.142 million in the third quarter of 2021, the company lost 4.0742 million Post date April 6, 2022 — 23:30 Post Lock Read More
Domestic PD-1 "involution" intensifies, BeiGene seeks to "break through" Europe Post date April 7, 2022 — 19:15 Post Lock Read More Shareholders of Yuheng Pharmaceuticals reduced their holdings of 37.1028 million shares to cash out about 80.142 million in the third quarter of 2021, the company lost 4.0742 million Post date April 6, 2022 — 23:30 Post Lock Read More
Shareholders of Yuheng Pharmaceuticals reduced their holdings of 37.1028 million shares to cash out about 80.142 million in the third quarter of 2021, the company lost 4.0742 million Post date April 6, 2022 — 23:30 Post Lock Read More
Caishen.CoCaishen.Co